Table 3.
Vessel density using optical coherence tomography angiography in each group.
| Bevacizumab group | PRP group | P value* | |
|---|---|---|---|
| VD of SCP | |||
| Baseline | 25.5 ± 5.8 | 22.9 ± 5.7 | 0.056 |
| 1 month | 25.5 ± 6.7 | 24.2 ± 7.3 | 0.442 |
| 3 months | 25.6 ± 6.8 | 26.5 ± 8.1 | 0.608 |
| 6 months | 25.7 ± 7.4 | 28.0 ± 8.5 | 0.892 |
| P value† | 0.350 | < 0.001 | |
| VD of DCP | |||
| Baseline | 19.9 ± 4.8 | 18.6 ± 4.5 | 0.219 |
| 1 month | 20.1 ± 4.4 | 18.9 ± 7.2 | 0.363 |
| 3 months | 20.2 ± 4.9 | 21.1 ± 7.6 | 0.586 |
| 6 months | 21.1 ± 7.6 | 22.4 ± 5.0 | 0.650 |
| P value | 0.130 | < 0.001 | |
Values in boldface (P < 0.05) are statistically significant.
All values are expressed as the mean ± SD (%).
VD vessel density, SCP superficial capillary plexus, DCP deep capillary plexus.
*Calculated for ANCOVA after adjusting for age.
†Calculated for repeated-measures ANOVA.